TG Therapeutics (NASDAQ:TGTX) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.17 by 82.35 percent. This is a 142.86 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $120.86 million which beat the analyst consensus estimate of $118.43 million by 2.05 percent. This is a 90.40 percent increase over sales of $63.47 million the same period last year.